Male Breast Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00017394Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerTreatment
NCT00119262Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerTreatment